Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1321 of 5804
-
Hypnosis app aims to tame hot flashes for breast cancer patients
Symptom relief Recruiting nowPatients treated for breast cancer with hormone therapy (HT) suffer from hot flashes. This side effect impacts treatment adherence. Indeed, approximately 50% of women take less than 80% of the prescribed dose, and up to 50% abandon their treatment before the fifth year of prescri…
Phase: NA • Sponsor: Institut de Cancérologie de Lorraine • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Hair loss pill for women? new trial tests oral minoxidil
Disease control Recruiting nowThe goal of this clinical trial is to learn about oral minoxidil 1mg in the treatment of women with androgenetic alopecia, a type of hormone-imbalanced hair loss. The main questions to answer are to know about that minoxidil 1mg is as effective as minoxidil 2% topical solution (…
Phase: PHASE3 • Sponsor: Industrial Farmacéutica Cantabria, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Engineered immune cells take on liver cancer in early trial
Disease control Recruiting nowThis is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments.
Phase: PHASE1 • Sponsor: Shanghai Ruiliyuan Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug shows promise for swallowing disorder
Disease control OngoingPhase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
Phase: PHASE2 • Sponsor: Uniquity One (UNI) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Promising drug for kids with rare muscle disease moves to next phase
Disease control Recruiting nowThe purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
Phase: PHASE2, PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New blood test uses AI and lasers to spot High-Risk breast cancer
Diagnosis Recruiting nowEXoPERT has developed a liquid biopsy-based in vitro diagnostic medical device that can diagnose cancer through blood. The in vitro diagnostic medical device for this clinical performance trial is a test device that applies a technology that measures Raman spectroscopic signals o…
Sponsor: EXoPERT • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
App-Based therapy aims to slow down paranoia in psychosis
Symptom relief Recruiting nowWorries about harm from others (also known as paranoia) are common. Thinking fast or going on gut feelings is natural but can fuel these worries. For some, fast thinking and worries start to get in the way of life. Cognitive behaviour therapy for psychosis (CBTp) is the recommend…
Phase: NA • Sponsor: King's College London • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Could a nitric oxide mist fight tough lung infections?
Disease control OngoingA Phase 1/2a, Multi-Centre, Randomised, Open-label study to assess the safety, tolerability, PK, and efficacy of RESP30X in Adult NCFB participants with confirmed high-titre respiratory PPMs.
Phase: PHASE1, PHASE2 • Sponsor: Thirty Respiratory Limited • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Alzheimer's polypill shows promise in early trial
Disease control CompletedThis is an estimation-focused Phase 2 study designed to explore and quantify treatment-related changes across multiple clinical outcomes in patients with Alzheimer's disease over a 210-day period. The anticipated study population are males and females aged 50-85 years with very m…
Phase: PHASE2 • Sponsor: Noah Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a ketamine mist lift severe depression fast?
Symptom relief Recruiting nowThis is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
Phase: PHASE3 • Sponsor: Theresa Jacob, PhD, MPH • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New test could spot tumours that dodge radiotherapy
Knowledge-focused Recruiting nowApproximately 50% of cancer patients with solid tumours will be treated with radiotherapy. A significant proportion (\>25%) of patients have hypoxic tumours which respond poorly to radiotherapy. Hypoxic tumours have a poor prognosis. This can be improved with treatment intensific…
Sponsor: University of Manchester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New app aims to ease mental health struggles after ICU stays
Symptom relief Recruiting nowConditions treated in intensive care units (ICUs) such as the acute respiratory distress syndrome (ARDS), congestive heart failure, COVID pneumonia, and sepsis are common. These can lead to high rates of depression, anxiety, and PTSD that worsen quality of life. Yet there are few…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
New hope for muscle stiffness: experimental drug ATX-01 enters human trials
Disease control Recruiting nowThe goal of this clinical trial is to test ATX-01 in participants with myotonic dystrophy type 1 (DM1). The main question it aims to answer is if ATX-01 is safe and well tolerated. The trial will compare the safety and tolerability of ATX-01 and a matching placebo. There will be…
Phase: PHASE1, PHASE2 • Sponsor: ARTHEx Biotech S.L. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control Recruiting nowTo find a recommended dose of the combination of alpelisib and pembrolizumab that can be given to patients with metastatic breast cancer or melanoma.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New program aims to get young hispanic cancer survivors moving again
Disease control Recruiting nowThis clinical trial tests the impact of a culturally-tailored home-based physical activity program on physical fitness in Hispanic or Latino/Latina adolescent and young adult (AYA) childhood cancer survivors. After treatment for cancer, some AYA survivors experience long-term eff…
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New 'Smart Bomb' radiation therapy targets multiple cancers in early trial
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma …
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New epilepsy drug tested as standalone treatment
Disease control OngoingCenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, the…
Phase: PHASE4 • Sponsor: SK Life Science, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Electric field therapy plus immunotherapy tested for tough lung cancers
Disease control TerminatedThe purpose of the study is to test the effectiveness and safety of TTFields therapy, delivered using the NovoTTF-200T device, concomitant with pembrolizumab in subjects with metastatic NSCLC previously treated with a PD-1/PD-L1 inhibitor and platinum-based chemotherapy.
Phase: PHASE2 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Hope for rare fat disorder: new drug shows promise in Long-Term trial
Disease control Recruiting nowThis Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Poop pills from different donors: a new hope for ulcerative colitis?
Disease control CompletedInflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), affects over 2 million people worldwide . Although biological therapies have significantly improved the treatment outcomes for UC, nearly two-thirds of patients experience diminishing dr…
Phase: NA • Sponsor: First Affiliated Hospital of Kunming Medical University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC